Clinical Observation Of Shenhu Wendan Decoction In Treating Patients With Premature Ventricular Contractions In Coronary Heart Disease(Phlegm Dampness Block Type)

Objective:To observe the clinical efficacy and safety of modified Shenhu Wendan Decoction in treating patients with premature ventricular contractions in coronary heart disease(phlegm dampness block type).Methods:Ninety patients who visited the Second Department of Cardiology at the Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine from December 2021 to December 2022 were selected.The selected patients met the TCM diagnostic criteria for palpitations(phlegm dampness block type)and the Western medicine diagnostic criteria for premature ventricular contractions in coronary heart disease,with LOWN grading of II-III.They were randomly divided into an experimental group and a control group,with 45 patients in each group.Both groups received basic treatment for coronary heart disease,while the control group received metoprolol succinate sustained-release tablets,the experimental group was treated with modified Shenhu Wendan Decoction for 4 weeks.Detailed records of the total score of TCM syndromes,single score of TCM syndromes,24-hour dynamic electrocardiogram,LOWN grading of premature ventricular contractions,heart rate variability and quality of life assessment scale(SF-12)scores,as well as adverse events during medication were recorded before and after treatment in two groups.SPSS26.0 software was used to analyze and process the clinical efficacy and safety of modified Shenhu Wendan Decoction in treating patients with premature ventricular contractions in coronary heart disease(phlegm dampness block type).Results:1.TCM Syndrome Curative Effect: Before treatment,there was no significant difference(P>0.05)in the total and individual TCM syndrome scores between the two groups.After 4 weeks of treatment,the total and individual TCM syndrome scores of both groups decreased compared to before treatment(P<0.05);compared with the control group,the experimental group showed a more significant decrease(P<0.05);the effective rate of TCM syndrome in the experimental group was 93.02%,while the effective rate in the control group was 62.79%.The therapeutic effect of the experimental group was significantly better than that of the control group(P<0.05),and the difference was statistically significant.2.Efficacy of 24-hour dynamic ECG: Before treatment,there was no significant difference in the number of 24-hour premature ventricular contractions between the two groups(P>0.05).After 4 weeks of treatment,the number of 24-hour premature ventricular contractions in both groups decreased(P<0.05);compared with the control group,the reduction degree of the experimental group was better than that of the control group(P<0.05);the effective rate of 24-hour dynamic electrocardiogram in the experimental group was 95.35%,while the effective rate in the control group was 79.07%.The therapeutic effect of the experimental group was better than that of the control group,and the difference was statistically significant(P<0.05).3.LOWN grading efficacy: Before treatment,there was no significant difference in the level of LOWN grading between the two groups(P>0.05).After 4 weeks of treatment,both groups showed a decrease in LOWN grading(P<0.05);the effective rate of LOWN grading in the experimental group was88.37%,while the effective rate in the control group was 67.44%,the therapeutic effect of the experimental group was better than that of the control group,and the difference was statistically significant(P<0.05).4.Heart rate variability efficacy: Before treatment,there was no significant difference in heart rate variability indicators between the two groups(P>0.05).After 4 weeks of treatment,compared with before treatment,all indicators of heart rate variability in the two groups were significantly improved(P<0.05);and the improvement degree of the experimental group was significantly better than that in the control group,with a statistically significant difference(P<0.05).5.Quality of Life Score(SF-12)Efficacy: Before treatment,there was no significant difference in the quality of life scores between the two groups(P>0.05).After 4 weeks of treatment,the quality of life scores of both groups of patients decreased(P<0.05);the degree of decline in the experimental group was significantly higher than that in the control group,with a statistically significant difference(P<0.05).Conclusion:1.Modified Shenhu Wendan Decoction can reduce the total and individual syndrome scores of TCM in patients with premature ventricular contractions in coronary heart disease(phlegm dampness block type),and improve their clinical symptoms;2.Modified Shenhu Wendan Decoction can reduce the frequency and degree of LOWN grading in patients with premature ventricular contractions in coronary heart disease(phlegm dampness block type),improve heart rate variability indicators,and improve patients’ quality of life;3.Modified Shenhu Wendan Decoction has no adverse reactions and is safe and reliable.